Immunity-inducing agent
This application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from (a) polypeptides consisting of amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, (b) polypeptides having a sequence identity of 85% or more with the amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, and (c) polypeptides comprising the polypeptides according to (a) or (b) as the partial sequences, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo.
1. A method of inducing an immune response in a cancer patient, said method comprising administering an effective amount of an immunity-inducing agent to said cancer patient;
wherein said immunity-inducing agent comprises, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from:
a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 8, 4, or 10;
wherein the cancer is a CSPG5 expressing cancer.
2. The method of inducing immunity according to claim 1 , wherein the polypeptide having immunity-inducing activity is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 8, 4, or 10.
3. The method of inducing immunity according to claim 1 , further comprising administering an immunoenhancer to said cancer patient.
4. The method of inducing immunity according to claim 3 , wherein the immunoenhancer is at least one selected from the group consisting of a Freund's incomplete adjuvant, Montanide, Poly IC and derivatives thereof, CpG oligonucleotides, interleukin 12, interleukin 18, interferon α, interferon β, interferon ω, interferon γ, and a Flt 3 ligand.
5. A method of treating cancer, said method comprising administering a pharmaceutical composition comprising an immunity-inducing agent and a pharmaceutically acceptable carrier to a subject in need thereof;
wherein said immunity-inducing agent comprises, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from
a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 8, 4, or 10;
wherein the cancer is a CSPG5 expressing cancer.
6. The method of treatment according to claim 5 , wherein the polypeptide having immunity-inducing activity is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 8, 4, or 10.
7. The method of treatment according to claim 5 , wherein the cancer is brain tumor, leukemia, malignant lymphoma, or neuroblastoma.
8. The method of treatment according to claim 5 , wherein said pharmaceutical composition comprises an immunoenhancer.
9. The method of treatment according to claim 8 , wherein the immunoenhancer is at least one selected from the group consisting of a Freund's incomplete adjuvant, Montanide, Poly IC and derivatives thereof, CpG oligonucleotides, interleukin 12, interleukin 18, interferon α, interferon β, interferon ω, interferon γ, and a Flt 3 ligand.
10. The method of treatment according to claim 5 , wherein the cancer is a brain tumor;
wherein the polypeptide having immunity-inducing activity is SEQ ID NO: 8; and
wherein the pharmaceutical composition comprises an immunoenhancer of Poly IC or a derivative thereof.